Clinical Trials Browser

Withdrawn × Interventional × romidepsin × Clear all

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Phase 1 Withdrawn

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Phase 3 Withdrawn

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02281279 2016-08-11

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT00085527 2013-09-05

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Phase 2 Withdrawn

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Clinical Trials

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer